Skip to content

3349.T

COSMOS Pharmaceutical Corporation

プライム · 小売業 · 小売 · JP

JPY 6,672.00
+4.02%
Ask drillr

Year over year

Reported trailing growth

Revenue
+6.7%
EBITDA
EBIT
+3.6%
EPS
-14.1%
Free cash flow
Operating cash flow

Forward estimates

Based on analyst estimates

Revenue
-1.2%
EBITDA
EPS
-1.2%

Three-year CAGR

Revenue
+10.2%
EBITDA
+11.7%
EBIT
+10.7%
Net income
+10.2%
EPS
-12.6%
Free cash flow
-35.3%

Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Feb 1, 2026